The University of Chicago Header Logo

Connection

Stephen Hanauer to Inflammatory Bowel Diseases

Back to Details
This is a "connection" page, showing publications Stephen Hanauer has written about Inflammatory Bowel Diseases.
Stephen Hanauer
Connection Strength
15.647
Inflammatory Bowel Diseases
  1. Corticosteroid Use in Randomized Clinical Trials of Biologics and Small Molecules in Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis. 2025 May 12; 31(5):1430-1440.
    View in: PubMed
    Score: 0.568
  2. Genetic polymorphisms impacting clinical pharmacology of drugs used to treat inflammatory bowel disease: a precursor to multi-omics approach to precision medicine. Expert Rev Clin Immunol. 2025 Apr; 21(4):461-472.
    View in: PubMed
    Score: 0.558
  3. The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2023 Jul-Dec; 19(9):1075-1089.
    View in: PubMed
    Score: 0.496
  4. Hospitalization Experiences and Post-traumatic Stress in Inflammatory Bowel Disease: Opportunities for Change. Inflamm Bowel Dis. 2023 05 02; 29(5):675-683.
    View in: PubMed
    Score: 0.493
  5. COVID-19 and Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2023 03; 52(1):103-113.
    View in: PubMed
    Score: 0.477
  6. Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes. Inflamm Bowel Dis. 2022 05 04; 28(5):710-719.
    View in: PubMed
    Score: 0.461
  7. Review article: drug-induced small bowel injury. Aliment Pharmacol Ther. 2021 12; 54(11-12):1370-1388.
    View in: PubMed
    Score: 0.444
  8. Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape. Curr Gastroenterol Rep. 2021 Aug 02; 23(9):16.
    View in: PubMed
    Score: 0.437
  9. Executive Summary of 'Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States'. Am J Gastroenterol. 2020 09; 115(9):1362-1366.
    View in: PubMed
    Score: 0.410
  10. Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States. Inflamm Bowel Dis. 2020 08 20; 26(9):1291-1305.
    View in: PubMed
    Score: 0.409
  11. Drug-Induced Colitis. Clin Gastroenterol Hepatol. 2021 09; 19(9):1759-1779.
    View in: PubMed
    Score: 0.401
  12. Initial Assessment of Post-traumatic Stress in a US Cohort of Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. 2019 08 20; 25(9):1577-1585.
    View in: PubMed
    Score: 0.382
  13. Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of Psychopathology. Inflamm Bowel Dis. 2019 08 20; 25(9):e114.
    View in: PubMed
    Score: 0.382
  14. Perspectives of Clinicians in the United States and Europe on Monitoring Levels of Biologic Agents in Patients Receiving Biologic Therapies for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 08; 17(9):1718-1723.
    View in: PubMed
    Score: 0.378
  15. More Than a Tumor Marker…A Potential Role for Alpha-Feto Protein in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 06 18; 25(7):1271-1276.
    View in: PubMed
    Score: 0.377
  16. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf. 2015; 14(12):1915-34.
    View in: PubMed
    Score: 0.294
  17. Reply: To PMID 25311382. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2384-5.
    View in: PubMed
    Score: 0.288
  18. Heading back to the trough (levels of biologics in IBD). Clin Gastroenterol Hepatol. 2015 Mar; 13(3):548-51.
    View in: PubMed
    Score: 0.273
  19. Comparing guidelines for the treatment of inflammatory bowel disease. Dig Dis. 2013; 31(3-4):360-2.
    View in: PubMed
    Score: 0.256
  20. Disease modification in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012 Sep; 10(9):954-5.
    View in: PubMed
    Score: 0.232
  21. Management of inflammatory bowel disease: past, present and future. Expert Rev Clin Immunol. 2012 May; 8(4):303-5.
    View in: PubMed
    Score: 0.230
  22. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011 Apr; 106(4):685-98.
    View in: PubMed
    Score: 0.213
  23. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11.
    View in: PubMed
    Score: 0.209
  24. Inflammatory bowel disease. Expert Rev Clin Immunol. 2010 Jul; 6(4):499-500.
    View in: PubMed
    Score: 0.203
  25. Devolving therapeutic pyramids. Nat Rev Gastroenterol Hepatol. 2010 Mar; 7(3):119-20.
    View in: PubMed
    Score: 0.198
  26. The expanding role of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010 Feb; 7(2):63-4.
    View in: PubMed
    Score: 0.197
  27. Optimizing conventional therapies for inflammatory bowel disease. Curr Gastroenterol Rep. 2009 Dec; 11(6):496-503.
    View in: PubMed
    Score: 0.195
  28. Don't miss the forest for the trees. Inflamm Bowel Dis. 2009 Sep; 15(9):1397-8.
    View in: PubMed
    Score: 0.191
  29. Exploring the controversial themes of IBD. Inflamm Bowel Dis. 2009 Sep; 15 Suppl 1:S1-10.
    View in: PubMed
    Score: 0.191
  30. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2009 Jun; 3(3):235-48.
    View in: PubMed
    Score: 0.188
  31. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S202-8.
    View in: PubMed
    Score: 0.188
  32. Semantics. Nat Clin Pract Gastroenterol Hepatol. 2008 Feb; 5(2):59.
    View in: PubMed
    Score: 0.171
  33. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008 Jan 21; 14(3):354-77.
    View in: PubMed
    Score: 0.171
  34. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8(3):159-68.
    View in: PubMed
    Score: 0.170
  35. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut. 2007 Sep; 56(9):1181-3.
    View in: PubMed
    Score: 0.167
  36. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007 Feb; 5(2):209-14.
    View in: PubMed
    Score: 0.160
  37. The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 3:S1-2.
    View in: PubMed
    Score: 0.159
  38. Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions. Rev Gastroenterol Disord. 2007; 7 Suppl 3:S3-10.
    View in: PubMed
    Score: 0.159
  39. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):757-73.
    View in: PubMed
    Score: 0.158
  40. The 'tipping point' applied. Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):59.
    View in: PubMed
    Score: 0.149
  41. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006 Jan; 12 Suppl 1:S3-9.
    View in: PubMed
    Score: 0.148
  42. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005 Sep 01; 22(5):441-6.
    View in: PubMed
    Score: 0.145
  43. An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease. Gastroenterology. 2025 Nov; 169(6):1282-1293.
    View in: PubMed
    Score: 0.142
  44. Assessment, prevention and treatment of osteoporosis in inflammatory bowel disease patients: a bone of contention. Nat Clin Pract Gastroenterol Hepatol. 2005 May; 2(5):199.
    View in: PubMed
    Score: 0.142
  45. COLAL-PRED Alizyme. Curr Opin Investig Drugs. 2004 Nov; 5(11):1192-7.
    View in: PubMed
    Score: 0.137
  46. Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol. 2003 Dec; 98(12 Suppl):S18-23.
    View in: PubMed
    Score: 0.128
  47. Post-traumatic stress disorder symptoms are frequent among inflammatory bowel disease patients of South Asian descent-A case-control study. Indian J Gastroenterol. 2024 02; 43(1):244-253.
    View in: PubMed
    Score: 0.127
  48. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98(6):1309-14.
    View in: PubMed
    Score: 0.124
  49. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(2):81-92.
    View in: PubMed
    Score: 0.121
  50. Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2023 04; 21(4):878-890.
    View in: PubMed
    Score: 0.119
  51. Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy. Inflamm Bowel Dis. 2022 10 03; 28(10):1603-1606.
    View in: PubMed
    Score: 0.119
  52. New steroids for IBD: progress report. Gut. 2002 Aug; 51(2):182-3.
    View in: PubMed
    Score: 0.117
  53. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
    View in: PubMed
    Score: 0.116
  54. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep. 2021 Dec 16; 23(12):30.
    View in: PubMed
    Score: 0.112
  55. Patient Perspectives on Medical Trauma Related to Inflammatory Bowel Disease. J Clin Psychol Med Settings. 2022 09; 29(3):596-607.
    View in: PubMed
    Score: 0.109
  56. Evolving treatment strategies for inflammatory bowel disease. Annu Rev Med. 2001; 52:299-318.
    View in: PubMed
    Score: 0.105
  57. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000 Nov; 23(5):429-48.
    View in: PubMed
    Score: 0.104
  58. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000 Aug; 12(8):855-62.
    View in: PubMed
    Score: 0.102
  59. Evolutionary biologic therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 1999 Dec; 1(6):467-9.
    View in: PubMed
    Score: 0.097
  60. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am. 1999 Jun; 28(2):297-321.
    View in: PubMed
    Score: 0.094
  61. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol. 2019 05; 75(5):846-852.
    View in: PubMed
    Score: 0.091
  62. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study). Aliment Pharmacol Ther. 2018 Apr; 47(8):1092-1102.
    View in: PubMed
    Score: 0.086
  63. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? Gastroenterology. 2018 03; 154(4):1201-1202.
    View in: PubMed
    Score: 0.086
  64. How do I treat erythema nodosum, aphthous ulcerations, and pyoderma gangrenosum? Inflamm Bowel Dis. 1998 Feb; 4(1):70; discussion 73.
    View in: PubMed
    Score: 0.086
  65. The Influence of Methotrexate Treatment on Male Fertility and Pregnancy Outcome After Paternal Exposure. Inflamm Bowel Dis. 2017 04; 23(4):561-569.
    View in: PubMed
    Score: 0.081
  66. Vitamin D Levels and Outcomes in Inflammatory Bowel Disease-Which is the Chicken and Which is the Egg? Clin Gastroenterol Hepatol. 2017 02; 15(2):247-248.
    View in: PubMed
    Score: 0.079
  67. Integrating Adolescents and Young Adults into Adult-Centered Care for IBD. Curr Gastroenterol Rep. 2016 May; 18(5):21.
    View in: PubMed
    Score: 0.076
  68. New therapeutic approaches. Gastroenterol Clin North Am. 1995 Sep; 24(3):523-40.
    View in: PubMed
    Score: 0.073
  69. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38.
    View in: PubMed
    Score: 0.072
  70. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):348-354.e17.
    View in: PubMed
    Score: 0.071
  71. Medical therapy of inflammatory bowel disease. Med Clin North Am. 1994 Nov; 78(6):1413-26.
    View in: PubMed
    Score: 0.068
  72. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014 Sep; 8(9):927-35.
    View in: PubMed
    Score: 0.066
  73. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest. 2013 Sep; 123(9):3983-96.
    View in: PubMed
    Score: 0.063
  74. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013 Mar; 19(3):662-8.
    View in: PubMed
    Score: 0.061
  75. What changes in inflammatory bowel disease management can be implemented today? J Crohns Colitis. 2012 Feb; 6 Suppl 2:S260-7.
    View in: PubMed
    Score: 0.057
  76. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf. 1991 May-Jun; 6(3):192-219.
    View in: PubMed
    Score: 0.054
  77. Aminosalicylates: old and new. Mt Sinai J Med. 1990 Oct; 57(5):283-7.
    View in: PubMed
    Score: 0.052
  78. Inflammatory bowel disease revisited: newer drugs. Scand J Gastroenterol Suppl. 1990; 175:97-106.
    View in: PubMed
    Score: 0.049
  79. A poor view from specialty silos. Nat Rev Gastroenterol Hepatol. 2010 Jan; 7(1):1-2.
    View in: PubMed
    Score: 0.049
  80. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007 Jul; 133(1):312-39.
    View in: PubMed
    Score: 0.041
  81. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S22-8.
    View in: PubMed
    Score: 0.037
  82. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jul; 2(7):308-15.
    View in: PubMed
    Score: 0.036
  83. The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease. Inflamm Bowel Dis. 2024 11 04; 30(11):2064-2075.
    View in: PubMed
    Score: 0.034
  84. Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(2):66-85.
    View in: PubMed
    Score: 0.032
  85. Evidence for an inflammatory bowel disease locus on chromosome 3p26: linkage, transmission/disequilibrium and partitioning of linkage. Hum Mol Genet. 2002 Oct 01; 11(21):2599-606.
    View in: PubMed
    Score: 0.030
  86. Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease. Hum Mol Genet. 2000 May 22; 9(9):1425-32.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.